Logo
x

Search category

Subscribe Now

Junshi Biosciences

Junshi Biosciences Reports the NMPA Acceptance of sNDA of Toripalimab as 1L Treatment of Extensive-Stage Small Cell Lung Cancer

Junshi Biosciences Reports the NMPA Acceptance of sNDA of Toripalimab as 1L Treatment of Extensive-Stage Small Cell Lung Cancer

  • July 20, 2023
Junshi Biosciences Reports the NMPA Acceptance of sNDA for Toripalimab + Axitinib as 1L Treatment of Unresectable or Metastatic Renal Cell Carcinoma

Junshi Biosciences Reports the NMPA Acceptance of sNDA for Toripalimab + Axitinib as 1L Treatment of Unresectable or Metastatic Re...

  • July 12, 2023
Junshi Biosciences Reports the NMPA Acceptance of sNDA of Toripalimab for Advanced Triple-Negative Breast Cancer

Junshi Biosciences Reports the NMPA Acceptance of sNDA of Toripalimab for Advanced Triple-Negative Breast Cancer

  • May 23, 2023
Junshi Biosciences Collaborated with Dr. Reddy’s to Develop and Commercialize Toripalimab for the Treatment of Cancer

Junshi Biosciences Collaborated with Dr. Reddy’s to Develop and Commercialize Toripalimab for the Treatment of Cancer

  • May 9, 2023
Junshi Biosciences Presents P-III Study (Neotorch) Results of Toripalimab for Resectable Stage III Non-small Cell Lung Cancer at ASCO 2023

Junshi Biosciences Presents P-III Study (Neotorch) Results of Toripalimab for Resectable Stage III Non-small Cell Lung Cancer at A...

  • April 21, 2023
Junshi Biosciences Reports P-III Study (FLAMES) Results of Senaparib for Advanced Ovarian Cancer

Junshi Biosciences Reports P-III Study (FLAMES) Results of Senaparib for Advanced Ovarian Cancer

  • April 12, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.